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Available online 22 June 2016Clevidipine, a dihydropyridine (DHP) analogue, lowers blood pressure (BP) by inhibiting L-type calcium channels
(CaV1.2; gene CACNA1C) predominantly located in vascular smooth muscle (VSM). However, clinical observa-
tions suggest that clevidipine acts by amore complexmechanism. Clevidipinemore potently reduces pulmonary
vascular resistance (PVR) than systemic vascular resistance and its spectrum of effects on PVR are not shared by
other DHPs. Clevidipine has potent spasmolytic effects in peripheral arteries at doses that are sub-clinical for BP
lowering and, in hypertensive acute heart failure, clevidipine, but not other DHPs, provides dyspnea relief, par-
tially independent of BP reduction. These observations suggest that a molecular variation in CaV1.2 may exist
which confers unique pharmacology to different DHPs. We sequenced CACNA1C transcripts from human lungs
and measured their afﬁnity for clevidipine. Human lung tissue contains CACNA1C mRNA with many different
splice variations. CaV1.2 channels with a speciﬁc combination of variable exons showed higher afﬁnity for
clevidipine, well below the concentration associated with BP reduction. Co-expression with pannexin 1 further
increased the clevidipine afﬁnity for this CaV1.2 splice variant. A high-afﬁnity splice variant of CaV1.2 in combina-
tion with pannexin 1 could underlie the selective effects of clevidipine on pulmonary arterial pressure and on
dyspnea.
Research in Context: Clevidipine lowers blood pressure by inhibiting calcium channels in vascular smoothmuscle.
In patients with acute heart failure, clevidipine was shown to relieve breathing problems. This was only partially
related to the blood pressure lowering actions of clevidipine and not conferred by another calcium channel inhib-
itor. We here found calcium channel variants in human lung that are more selectively inhibited by clevidipine,
especiallywhen associatedwith pannexin channels. This study gives a possiblemechanism for clevidipine's relief
of breathing problems and supports future clinical trials testing the role of clevidipine in the treatment of acute
heart failure.







Hypertensive heart failure1. Introduction
Clevidipine is a 3rd generation dihydropyridine (DHP) that lowers
blood pressure via selective antagonism of peripheral vascular
smooth muscle (VSM) voltage-gated L-type calcium channels (CaV1.2)
(Fig. 1A). Recently, clinical observations suggest that the mechanisms
of clevidipine action are more complex than simple antagonism of pe-
ripheral VSM CaV1.2. In a clinical trial examining the safety and efﬁcacyy and Biophysics, RMSB Room
i, FL 33101, United States.
n).
. This is an open access article underof clevidipine for blood pressure (BP) reduction in hypertensive acute
heart failure (AHF), clevidipine showed a superior dyspnea-relieving
beneﬁt versus standard of care intravenous (IV) antihypertensives,
including another DHP (Peacock et al., 2014). When compared to
standard of care, dyspnea relief in patients receiving clevidipine was
more robust and faster, and this beneﬁt was only partially related to
the blood pressure lowering actions of clevidipine. Importantly, this
beneﬁt was not conferred by nicardipine, another L-type blocking DHP
agent. Clevidipine is also a potent pulmonary vasodilator with most of
the PVR reduction occurring at doses that are lower than those needed
to cause the majority of the reduction of systemic blood pressure
(Cleviprex package insert and (Kieler-Jensen et al., 2000)) (Fig. 1A).the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Putative Clevidipine targets for lowering blood pressure. A) Scheme showing putative Clevidipine targets (including Panx1) to lower blood pressure in lung and other tissues. B)
CaV1.2 α-1 subunit topology and location of spliced exons examined in this study.
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nitude of reduction are equivalent to thenitrovasodilators and clevidipine
is also effective in nitrate non-responders (Nordlander et al., 2004). Lastly,
similar to the observed potency increase for clevidipine effects on pulmo-
nary vascular resistance (PVR), clevidipine has a spasmolytic effect in
peripheral arteries that occurs at doses that are minimally effective for
BP reduction (Huraux et al., 1997; Patel et al., 2012). This dose-response
relationship between spasmolysis and BP reduction is not shared by
other DHPs (Schmidt et al., 2010). In this study, we applied a reverse
translational approach to understand these non-BP lowering effects of
clevidipine by conducting further basic science studies on an already ap-
proved clinical drug.
In the nearly 18 years since the clevidipine investigational new
drug application was ﬁled, our understanding of the structure, tissue
distribution and molecular biology of the L-type calcium channels
(LTCC) has evolved dramatically (Zuccotti et al., 2011; Abernethy and
Soldatov, 2002). The CaV-α-1 family comprises 10 genes, of which 4
genes (CACNA1S, CACNA1C, CACNA1D CACNA1F) encode the LTCC
referred to as CaV1.1, CaV1.2, CaV1.3 and CaV1.4 channels. LTCC are
distinguished from the other 6 CaV channels by their selective sensitiv-
ity to 1,4-dihydropyridines (DHPs), phenylalkylamines (PAAs) and
benzothiazepines and by their characteristic slowly inactivating cur-
rents. LTCCs are composed of a central pore-forming α-1 subunit and
additional α-2/δ, β, and γ subunits. The α-1 subunit confers most of
the functional properties to the channel, including voltage sensing, per-
meability, calcium-dependent inactivation, and sensitivity to organic
channel blockers. Although the α-1 subunit deﬁnes the basic channel
properties, four different β genes (β1–β4; genes CACNB1–4) and exten-
sive splice variants of each gene exist that distinctly modify activation
and inactivation kinetics, voltage gating, and drug sensitivity (Hullin et
al., 2003).
At least 20 of the 56 exons in the human CACNA1C transcript are al-
ternatively spliced (Liao et al., 2007) (Fig. 1B). Splice variants are known
to confer different electrophysiological and pharmacological properties
on the CaV1.2 channel and to exhibit tissue-speciﬁc differences (e.g. car-
diacmuscle vs. vascular smoothmuscle (VSM)) (Liao et al., 2007; Cheng
et al., 2009). Smoothmuscle is known to bemore sensitive to DHPs than
cardiac muscle (Moosmang et al., 2003). These tissues express slightly
different CaV1.2 splice variants (Cheng et al., 2009; Saada et al., 2003;
Liao et al., 2005): exon 8 is expressed in smooth muscle, while exon
8a is expressed in cardiac muscle. Exon 8a in cardiac tissue reducesthe afﬁnity of CaV1.2 for DHPs (Welling et al., 1997). Lastly, in addition
to themolecular heterogeneity conferred by differing subunit combina-
tions and alternative splice variants, disease-based differences in tissue
distribution and expression levels of any given channel complex are
common (Hullin et al., 2003; Firth et al., 2011). In this report, we tested
the hypothesis that, in lung tissue, there are speciﬁc CACNA1C splice
variants encoding for CaV1.2 with different molecular pharmacologic
proﬁles for clevidipine compared to CaV1.2 in other peripheral smooth
muscles (Fig. 1A).
In parallel to our increased understanding of CaV1.2 channels during
the last decade, a more detailed understanding of themolecular basis of
BP regulation has emerged. For example, pannexin 1 (gene PANX1),
which serves as the major ATP-release channel in many cell types
(including erythrocytes, endothelial cells, airway epithelial cells and
astrocytes (Locovei et al., 2006a; Ransford et al., 2009; Dahl and
Keane, 2012)), is involved in two antagonistic ways for blood ﬂow and
blood pressure regulation. 1) Erythrocytes sensing low oxygen content
and/or subjected to shear stress release ATP through Panx1 channels
(Locovei et al., 2006a; Sridharan et al., 2010). The ATP binds to purinergic
receptors on endothelial cells, triggering a propagated calciumwave that
eventually results in the release of nitric oxide (NO). NO then relaxes vas-
cular smooth muscle cells which increases local perfusion and oxygen
supply (Fig. 1A). 2) Activation ofα-adrenergic receptors leads to opening
of Panx1 channels in VSM cells and blocking of Panx1 channels in these
cells attenuates the vasopressor activity of α-agonists (Billaud et al.,
2012). Thus, it appears that Panx1 is tied into the α-adrenergic control
of blood pressure (Fig. 1A). In this report, we therefore also considered
the hypotheses that the clevidipine-induced dyspnea relief is due to
clevidipine acting on Panx1 in lung tissue. It is also known that Panx1
co-localizes with voltage-gated calcium channels (CaV1.1) in skeletal
muscle (Jorquera et al., 2013).We therefore also considered the possibil-
ity that Panx1 associates with CaV1.2 in lung tissue and increases the
afﬁnity of CaV1.2 to clevidipine.
2. Methods
2.1. Identiﬁcation of CaV1.2 Splice Variants in Lung Tissue
Human lung tissue (8 donors)without overt disease, but not suitable
for transplant, was obtained from the Life Alliance Organ Recovery
Agency according to institutional review board guidelines regarding
Table 2
Frequency of CaV1.2 variants.
Individual lung donors
A B C D E F G H
Exons 7–11 variants
7,8,9,10,11 9/9 9/19 16/18 11/16 11/13 12/17
7,8,9,9*,10,11 0 7/19 2/18 3/16 0/13 5/17
7,8,9,10,10*,11 0 1/19 0/18 1/16 0/13 0/17
7,8,9,9*,10,10*,11 0 1/19 0/18 0/16 0/13 0/17
7,-,-10,11 0 1/19 0/18 1/16 2/13 0/17
Exons 20–24 variants
20,21,-,23,24 10/10 8/8 10/10 10/10 10/10 9/9 0/8 9/9
20,-,22,23,24 0/10 0/8 0/10 0/10 0/10 0/9 8/8 0/9
Exons 30–34 variants
30,-,32-6 nt,33,34 1/9 2/9 2/8 0/9 0/9 0/8 0/7
30,-,32,-,34 3/9 3/9 0/8 3/9 2/9 2/8 1/7
30,-,32-6 nt,-,34 0/9 0/9 0/8 0/9 0/9 1/8 0/7
30,-,32,33,34 2/9 3/9 3/8 3/9 5/9 2/8 2/7
30,31,-,33,34 1/9 1/9 2/8 1/9 1/9 1/8 1/7
30,31,-,-,34 0/9 0/9 1/8 0/9 1/9 0/8 2/7
30,31,32,-,34 0/9 0/9 0/8 1/9 0/9 0/8 0/7
30,31,32,33,34 2/9 0/9 0/8 1/9 0/9 0/8 0/7
30,-,-,33,34 0/9 0/9 0/8 0/9 0/9 2/8 0/7
30,-,-,-,34 0/9 0/9 0/8 0/9 0/9 0/8 1/7
Exons 40–46 variants
40,41,42,43,44,-,46 9/9 8/8 3/3 9/10 8/8 14/14
40 + 57
nt,41,42,43,44,-,46
0/9 0/8 0/3 1/9 0/8 0/14
Italicized entries are not expected to be functional.
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acteristics, see Table 1). Peripheral lung tissue was excised, chopped
into ~5 mm fragments, and snap frozen in liquid N2. For preparation
of total RNA, tissue was ground in a mortar and pestle under liquid N2
and the powder immediately extracted using E.Z.N.A. HP Total RNA
Isolation Kit (Omega Bio-Tek, Norcross, GA). Total RNA was treated
with DNase I and reverse transcribed using AMV First Strand cDNA
Synthesis Kit (NewEngland Biolabs, Ipswich,MA)with a primer speciﬁc
in exon 50 of the CACNA1C transcript 3′ UTR (see Table 1 for primers
sequences). cDNA was ampliﬁed by 35 cycles of PCR using Hotstar
Hiﬁdelity Taq polymerase kit (Qiagen, Valencia, CA) with primers
speciﬁc for exons surrounding known spice sites (Table 2) and thePCR re-
actions cloned into pGEMTeasy. cDNA in random individual colonies was
isolated and sequenced.
2.2. Electrophysiology
Eight different full-length CACNA1C cDNAs (Table 3)were construct-
ed by combiningdifferent exons from theCaV1.2 splice variants found in
the human lung. These eight cDNAs were transferred into a Xenopus
oocyte expression vector and mRNAs were transcribed in vitro. 50 nl
of 1 μg/μl mRNA of the different splice variants of the α-1 subunit of
CaV1.2 together with its α-2/δ and β subunits were injected into
Xenopus oocytes. Currents were recorded 2–5 days after mRNA injec-
tion using two-electrode voltage clamp technique. Currents were ﬁl-
tered at 500 Hz and sampled at 5 kHz. Extracellular solution contained
(in mM): 20 barium acetate, 70 sodium glutamate, 5 HEPES, 2 KOH,
pH = 7.3. For recordings with Panx1, in vitro transcribed mRNAs for
Panx1 together withmRNA for alpha-1, alpha-2/delta and beta subunits
of CaV1.2were injected into Xenopus oocytes at equal ratios. Results are
given as mean ± SEM.
2.3. Funding
This study was funded by The Medicines Company (Parsippany NJ)
and a University of Miami SAC Award 2016-31R to GEC and HPL.
Funders had no role in study conduct, experimental conduct, data
collection or data analysis.
3. Results
3.1. Many Different CaV1.2 Splice Variants Present in Lung Tissue
From Individuals
Because clevidipine has greater potency for reducing PVR, it is possible
that, in human lungs, there is expressed a unique combination of CaV1.2
splice variants with a higher afﬁnity for clevidipine that CaV1.2 expressed
in other tissues. To test this idea, cDNA was prepared from human lung
parenchyma and used to amplify regions of CACNA1C known to have
substantial splicing variation: exons 7–11 (7,8,8a,9,9*,10,10*,11), 20–24
(20,21,22,23,24), 30–35 (30,31,32,33,34) and 40–46 (40,41,42,43,44,
45,46) (Fig. 1). Amplimers were not seen in controls using RNA without










Reverse exon50 TGTTCCGGTTAACTCCAGGTdifferent individuals displayed different frequencies of individual splice
variants (Table 2).
Five different variantswere detected between exons 7 and 11. As ex-
pected, only exon 8, and not the cardiac-speciﬁc alternate exon 8a, was
seen (Welling et al., 1997). The most common variant contained Exons
8, 9 and 10, skipped exons 9* and 10* (7,8,-,9,-,10,-,11), andwas present
in all individuals examined. This variant represented 74% of all ampliﬁed
cDNA fragments in this region (Table 2). The variant with exons 8, 9, 9*
and 10 (7,8,-,9,9*,10,-,11) was seen in 4 of 6 individuals and varied be-
tween 10 and 40% of the total isolates from an individual (Table 2).
Exons 8, 9, 10 and 10* (7,8,-,9,-,10,10*,11) and exons 8, 9, 9*, 10, 10*
(7,8,9,9*,10,10*,11) were seen in two of six individuals. Another variant
was detected that deleted exons 8, 9, 9* and 10* (7,-,-,-10,-11). Exon 8 is
believed to be required for functional CaV1.2 expression and thus this
variant is mostly likely not functional.
Only two splice variants were detected between exons 20 and 24
(20,21,-,23,24 and 20,-,22,23,24). Previously reported alternate exons
21 and 22 were never both present in an individual (Table 2). Exon 21
was present in seven of eight individuals.
Signiﬁcant variation was apparent between exons 30 and 34. Ten
different splice variants were detected, four of whichwere not expected
to be functional (Table 2). Two variants differing by the alternate exons
31 and 32 in combination with exon 33 (30,31,-,33,34 or 30,-,32,33,34)Table 3
IC50 andHill coefﬁcient for thedifferent CaV1.2 splice variants. IC50 andHill coefﬁcient (h)
from ﬁts of data as in Fig. 2 with the equation I (concentration) = I(0) ∗ 1 / (1 + (IC50 /
[concentration])h).
Clones Drug IC50 (μM) h
22-32-33 Clevidipine 0.22 0.85
22-32-33 Nicardipine 2.01 0.85
21-31-33 Clevidipine 0.19 0.82
22-31-delta33 Clevidipine 0.06 0.8
22-31-delta33 Nicardipine 0.885 1.03
22-32-delta33 Clevidipine 0.19 1.1
21-32-delta33 Clevidipine 0.28 1.04
21-31-delta33 Clevidipine 0.16 0.9
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from 20 to 50% of clones from a single individual and alternate exon 31
ranging between 10 and 25% in a single individual. In addition, exon 32
in the absence of exon 33(Δ33) was present in six of seven individuals
(30,-,32,-,34) with a frequency of 15–30%. Exon 31 in the absence of
exon 33 (30,31,-,-,34) was seen with less frequency (Table 2).
Only two splice variants between exons 40 and 46 were detected,
both lacking exon 45 (Δ45) and differing in the previously reported
presence or absence of 57 nucleotides appended to the 3′ end of exon
40 (Table 2). Exon 40 without an extension (40,41,42,43,44,-,46) was
expressed in all individuals examined and only one clone of ten isolated
from a single individual contained exon 40 with the 57 nucleotide
extension (40 nt,41,42,43,44,-,46).
3.2. Different Effects of Clevidipine on the Identiﬁed CaV1.2 Splice Variants
Because signiﬁcant CACNA1C splice variations in different exons
were seen both within individuals and between individuals, cDNAs
encoding combinations of these exon variants were constructed, tran-
scribed, and injected in Xenopus oocytes. We tested eight splice variant
combinations of CACNA1C exons found in human lung tissue (Table 3).
All of these eight variants had the same exons in the regions of exons
7–11 and 40–46 [i.e. (7,8,-,9,-,10,-,11), and (40,41,42,43,44,-,46)]. In
the regions of exons 20–24 and 30–34, they were variable in exons
21/22, 31/32 and whether exon 33 was present or absent. For example,
variant 22–31-Δ33 contains exons (7,8,-,9,-,10,-,11), (20,-,22,23,24),
(30,31,-,-,34), and (40,41,42,43,44,-,46). We recorded the currents
from these splice variants in response to a 0 mV depolarization from
a holding potential of −80 mV (Fig. 2A). Currents were recorded in
20 mM barium to avoid activating contaminating calcium-activated
chloride channels in Xenopus oocytes. Extracellular application ofFig. 2. CaV1.2 splice variants have different afﬁnity for clevidipine. (A and C) Currents from A)
holding voltage of−80 mV, followed by a tail voltage of−80 mV, in the presence of the ind
22-32-33 and D) 22-31-Δ33 CaV1.2 splice variants ﬁtted with Hill equation (See Table 3 for paclevidipine blocked the currents in a dose dependent manner
(Fig. 2A–B). Most of the different splice variants had similar currents
and similar responses to clevidipine (Fig. 2B; Table 3). For most of the
splice variants, the currents versus clevidipine concentration data could
be ﬁtted with a dose response curve with an IC50 around 200 nM. How-
ever, the splice variant combination 22-31-Δ33 showed an approximate-
ly 4-fold higher afﬁnity (IC50= 60 nM) for clevidipine compared to the
other tested splice variants (Fig. 2C-D; Table 3).
We also tested the effect of the DHP nicardipine for the different
CaV1.2 splice variants. Nicardipine also blocked current in a dose depen-
dent manner (Fig. 3). However, clevidipine showed an approximately
10-fold higher afﬁnity than nicardipine for the same CaV1.2 splice vari-
ants, including the high afﬁnity version (Table 3).
We conclude that CaV1.2 splice variantswith different clevidipine af-
ﬁnities are present in lung tissue and these higher afﬁnity variants also
show selective higher afﬁnity for one DHP versus another.3.3. Co-expression of CaV1.2 (22-31-Δ33) with Panx1 Boosts the Afﬁnity
to Clevidipine
Pannexin1 channels have been recognized to be involved in the con-
trol of smooth muscle contraction. In VSM, pannexin mediates both
muscle relaxation and contraction (Billaud et al., 2012; Locovei et al.,
2006b). It is therefore conceivable that clevidipine acts on Panx1 as an
epiphenomenon and that clevidipine either inhibits Panx1, thereby at-
tenuatingα-adrenergic contractions (Billaud et al., 2012), or stimulates
Panx1, thereby activating the NO-mediated relaxation. However, when
we tested the effects of clevidipine on Panx1 channel currents, we did
not observe any direct effect of clevidipine on Panx1 channels expressed
in Xenopus oocytes (Fig. 4A).the 22-32-33 and C) 22-31-Δ33 CaV1.2 splice variants in response to a 0 mV step from a
icated concentration of clevidipine. (B and D) Average dose response (n = 4) for B) the
rameters).
Fig. 3.CaV1.2 splice variants have lower afﬁnity for nicardipine. (A and C) Currents fromA) the 22-32-33 and C) 22-31-Δ33 CaV1.2 splice variants in response to a 0mV step from a holding
voltage of−80mV, followedby a tail voltage of−80mV, in thepresence of the indicated concentration of nicardipine. (B andD)Averagedose response (n=4) for B) the 22-32-33 andD)
22-31-Δ33 CaV1.2 splice variants ﬁtted with Hill equation (see Table 3 for parameters).
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CaV1.2 might alter the afﬁnity or behavior of the CaV1.2 in response to
clevidipine. I/V curves of oocytes co-expressing CaV1.2 and Panx1 chan-
nels exhibit a marked difference between co-expressing cells and cells
expressing Panx1 alone (Fig. 4B). The shift in reversal potential and the
attenuation of current amplitude are consistent with a CaV1.2-induced
switch of the chloride-selective Panx1 channel to the unselective Panx1
(Wang et al., 2014).
The effect of clevidipine on oocytes expressing CaV1.2 (22-32-33)
alone orwhen co-expressedwith Panx1was indistinguishable. However,
whenPanx1was co-expressedwith the high-afﬁnity splice variant CaV1.2
(22-32-Δ33) a signiﬁcant left-shift to lower clevidipine concentrations
was observed (Fig. 4C–D). No such augmentation for nicardipine afﬁnity
was observed (Fig. 4D).
4. Discussion
Herewe used a reverse translationalmedicine approach to address a
series of clinical observations (Peacock et al., 2014; Kieler-Jensen et al.,
2000; Patel et al., 2012) that indicate that the described mechanism of
action for clevidipine was incomplete. We hypothesized that molecular
variation in CaV1.2 channels exists which confers unique pharmacology
upon clevidipine.We report 4 principleﬁndings. 1)Manydifferent CaV1.2
splice variants are present in human lung. 2) Different CaV1.2 splice var-
iants have different afﬁnity for clevidipine. 3) Clevidipine has N10-fold
higher afﬁnity than another similar DHP, nicardipine, to certain CaV1.2
splice variants. 4) Panx1 and CaV1.2 interact, such that Panx1 lowers
the IC50 for CaV1.2 splice variants to clevidipine, but not to nicardipine.
The complexity of CACNA1C subunit splicing has been previously
reported (Hofmann et al., 2014). However, neither the distribution
among individuals nor the occurrence of variants in lung tissue hasbeen previously shown. We saw clear differences in expression among
individuals, including exons known to affect CaV1.2 functional charac-
teristics. Interestingly, all transcripts from one individual contained
either the alternate exon 21 or 22, i.e. no individual expressed both
20,21,-,23,24 and 20,-,22,23,24, whereas variants containing either of
the alternate exons 31 and 32 were found in all individuals. Although
the functional impact of co-expressing all of the different transcriptional
variants is not known, the differential expression could play a role
in known individual response variations to DHPs (Cook et al., 1990;
Taylor et al., 1985a,b; Schwieler et al., 1999).
We show that alternative CaV1.2 splice variants have different afﬁn-
ities for clevidipine. One of the tested CaV1.2 splice variants has an IC50
for clevidipine that is approximately 7-fold lower (60 nm) than the re-
ported IC50 for clevidipine in VSM (400 nM) (Nordlander et al., 2004).
This pharmacology offers a possible mechanistic explanation underly-
ing the PVR reducing and dyspnea relieving actions of clevidipine,
which both occur at lower doses than required for SVR reduction. In ad-
dition, we found that clevidipine has N10-fold higher afﬁnity than
nicardipine to speciﬁc CaV1.2 splice variants, which could be part of
the explanation for the speciﬁcity of the dyspnea effect of clevidipine
in AHF (Peacock et al., 2014; Cook et al., 1990).
In addition, we found that Panx1 and CaV1.2 interact, with Panx1 fur-
ther lowering the IC50 of CaV1.2 for clevidipine (but not for nicardipine).
Themechanism for howPanx1 alters the afﬁnity of CaV1.2 for clevidipine
is not clear, but ion conduction through the Panx1 channel is not neces-
sary for this effect (Fig. 5). Application of clevidipine in the continued
presence of the Panx1 inhibitor carbenoxolone (CBX) resulted in similar
clevidipine inhibition of the calcium currents as in the absence of CBX
(Fig. 5), indicating that the channel function of Panx1 is not required
for the Panx1-induced boost in clevidipine sensitivity of CaV1.2
(22,32,Δ33).
Fig. 4. Co-expression of Panx1with CaV1.2(Δ33) alters sensitivity to clevidipine. A). Clevidipine does not affect membrane currents in oocytes expressing Panx1 channels alone, while the
Panx1 blocker carbenoxolone (CBX) attenuates the currents. B). Membrane currents induced by voltage ramps from−100 mV to +100 mV in oocytes expressing Panx1 alone (blue
traces) and in oocytes co-expressing Panx1 and CaV1.2 (magenta). The exclusively voltage activated Panx1 channel is chloride selective, yielding a strong outward current at positive
potentials. The net current in the co = expressing cells is considerably smaller, likely because of the non-selective properties of the Panx1 channels under these experimental
conditions. A slight left shift of the reversal potential in the co-expressing cells is consistent with a change in permeability properties. C). Membrane currents induced by voltage steps
from−60 mV to +60 mV at 0.1 Hz in oocytes expressing CaV1.2 Δ33 alone (top traces) or oocytes co-expressing CaV1.2 Δ33 with Panx1. Records of identical oocytes are shown,
where increasing concentrations of clevidipine were applied with 30 minute intervals to allow recovery of the CaV1.2 channels from inactivation. D). Dose-response curves for
clevidipine attenuation of currents in oocytes expressing CaV1.2 Δ33 alone (black squares) or oocytes coexpressing Panx1 with CaV1.2 Δ33 (red circles). The co-expressing oocytes
were also exposed to Nicardipine (blue triangles).
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Panx1/CaV1.2 complex could contribute further to the speciﬁcity of the
dyspnea-relieving effect of clevidipine in AHF (Peacock et al., 2014;
Cook et al., 1990). This study shows that Panx1 association alters the af-
ﬁnity of an ion channel to its inhibitor. Although previous studies have
shown that CaV1.2 splice variants alter DHP sensitivity, this study
shows that different splice variants of CaV1.2 confer differences in the
speciﬁcity of different DHP.Fig. 5. Ionic currents through PNX1 are no necessary for Panx1 to increase the afﬁnity for
clevidipine in CaV1.2. Membrane currents observed in oocytes co-expressing Panx1 and
CaV1.2 (22,32,Δ33). The pulse protocol was the same as shown in Fig. 4C. After a series of
test pulses, oocytes were incubated in Ringer solution supplemented with the Panx1
inhibitor carbenoxolone (CBX), which did not interfere with the large calcium currents at
the begin of the pulse series, but attenuated the Panx1 currents remaining after the
inactivation of the calcium currents. Subsequent application of clevidipine in the continued
presence of CBX resulted in similar inhibition of the calcium currents as in the absence of
CBX (cf Fig. 4C).Further studies are needed to elucidate themechanism of how Panx1
affect CaV1.2 pharmacology. However, the Panx1/ CaV1.2 interaction ob-
served suggests a possible new paradigm for intracellular calcium regu-
lation: ampliﬁcation of Ca2+ inﬂux by Ca2+ activation of Panx1,
causing Panx1-mediated ATP release. ATP could then act on P2Y recep-
tors to further boost intracellular Ca2+ concentrations via Ca2+ release
from intracellular stores. Ampliﬁcation due to Panx1–mediated second-
ary ATP releasewas hitherto only known to boost the response to ligands
binding to various receptors, including α-adrenergic agonists, thrombin,
angiotensin II, histamine and bradykinin (Dahl, 2015).
A number of questions remain unaddressed. Harvested donor lung
likely includes mixed tissue, including lung parenchyma, arterioles,
venules, and airway, and, as a result, the tissue location and expression
pattern of the splice variants reported here remains unknown. It is pos-
sible that the described splice variants are present, but are not physio-
logically relevant for control of PVR or dyspnea relief. Although this
possibility seems unlikely, further studies are clearly needed to deﬁne
the contribution of these splice variants to both normal physiology
and the clinical pathophysiology of AHF. Finally, the extent of any co-
localization or co-expression of Panx1 with LTCC in VSM or lung tissue
remains unknown.
In summary, we here provide insights into questions raised as a re-
sult of clinical experiences: How does clevidipine cause dyspnea relief
in hypertensive AHF? What explains the speciﬁcity of this effect for
clevidipine andnot for otherDHPs?What underlies the apparent poten-
cy differences between clevidipine effects on pulmonary and peripheral
circulations? Could clevidipine cause dyspnea relief independent of any
BP lowering effects? We here describe new CaV1.2 splice variants in
human lung that have increased, selective afﬁnity for clevidipine com-
pared to other DHPs. Panx1 associationwith this high-afﬁnity CaV1.2 var-
iant further augments its afﬁnity for clevidipine, but not for nicardipine.
These observations could explain many of the clinical differences noted
297G.P. Dahl et al. / EBioMedicine 10 (2016) 291–297above. These experiments reﬁne our understanding of how CaV1.2 alter-
native splicing produces speciﬁc molecular pharmacologic proﬁles
among drugs of the same class. Because these pharmacologic proﬁles
can explain important clinical observations, the possibility now exists to
deploy more reﬁned clinical trial designs and endpoints to better exam-
ine the role of DHP in the treatment of pulmonary hypertension and
acute hypertensive heart failure.
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